Last reviewed · How we verify

NCT05887947

Impact of E-cigarette Nicotine Concentration on Compensation

Completed NA Results posted Last updated 10 September 2025
What this trial tests

NA trial testing Electronic Cigarette with 5% Nicotine Concentration in Smoking Cessation in 52 participants. Completed in 10 June 2024.

Timeline
20 February 2023
Primary endpoint
3 May 2024
10 June 2024

Quick facts

Lead sponsorUniversity of Kansas Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment52
Start date20 February 2023
Primary completion3 May 2024
Estimated completion10 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Kansas Medical Center

Who can join

21 and older, any sex, with Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Total Inhaled Volume Primary · 5 minutes

Differences within participants in total inhaled volume in electronic cigarette puff topography during the pharmacokinetic portions of lab visit 1 and 2

GroupValue95% CI
5% Nicotine E-cigarette416.5± 258.3
1.8% Nicotine E-cigarette490.3± 255.1
Participant Switch Trajectory Secondary · Week 6 of the Phase 2 period, approximately 8 weeks post-baseline

Switch trajectory: biochemically confirmed \[exhaled carbon monoxide\] complete switch, use of both e-cigarettes and cigarettes, use of only cigarettes, complete cessation \[non-use of e-cigarettes and cigarettes with biochemical confirmation\]

GroupValue95% CI
5% Nicotine E-cigarette10
1.8% Nicotine E-cigarette6
5% Nicotine E-cigarette10
1.8% Nicotine E-cigarette13
5% Nicotine E-cigarette3
1.8% Nicotine E-cigarette0
5% Nicotine E-cigarette1
1.8% Nicotine E-cigarette0

Sponsor's own description

The study will be the first to assess the impact of nicotine concentration on compensatory puffing (total inhaled volume), nicotine delivery, and switch patterns (percent exclusive EC, dual cig-EC, and cig only users) with an explicit focus on AA and White smokers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Electronic cigarettes for smoking cessation.
    Lindson N, Butler AR, McRobbie H, Bullen C, et al · · 2024 · cited 94× · PMID 38189560 · DOI 10.1002/14651858.cd010216.pub8
  2. Electronic cigarettes for smoking cessation.
    Lindson N, Butler AR, McRobbie H, Bullen C, et al · · 2025 · cited 32× · PMID 39878158 · DOI 10.1002/14651858.cd010216.pub9

Verify or expand the search:

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

Other University of Kansas Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing